Schrodinger, Inc. · NASDAQ:SDGR
Schrodinger — Q3 2026 Earnings Presentation
22 slides from Schrodinger's earnings presentation, Nov 4, 2026
Slide 1: Revolutionizing Medicines and Materials Discovery
Revolutionizing Medicines and Materials Discovery October 2026
Slide 2: Cautionary Note and Disclaimer
Cautionary Note and Disclaimer This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, made by Schröding
Slide 3: Recent Updates
Recent Updates 3Q26 Financials Platform & Portfolio • $44.7M ACV (+17%) • Bunsen early access program ongoing – +24% excluding contribution ACV • Co-founded Tectora Therapeutics • Total revenue: $64.5M (+19%) – Raised $55M Series A with New Enterprise Associates (NEA) and RA Capital • Hosted revenue
Slide 4: Multi-Pronged Business Enabled by Highly Differentiated Computational Platform
Multi-Pronged Business Enabled by Highly Differentiated Computational Platform SOFTWARE LICENSING THERAPEUTICS PORTFOLIO • Accelerating molecular design for Life • Full-scale application of predict-first Sciences and Materials Science global approach producing highly differentiated customers molecul
Slide 5: Schrödinger's Vision for the Future of Molecular Discovery
Schrödinger’s Vision for the Future of Molecular Discovery If all properties can be calculated with perfect accuracy, designing drugs/materials would have a much higher success rate, be much faster and cheaper, and would produce much higher-quality molecules. Select THE best molecule Physics-powered
Slide 6: Schrödinger's Platform Uniquely Addresses the Challenge of Data Scarcity in Molecular Discovery
Schrödinger’s Platform Uniquely Addresses the Challenge of Data Scarcity in Molecular Discovery Highly sophisticated Simulated data is needed AI applications rely on to unlock power of AI simulated data Autonomous Vehicles Weather Prediction AI models in molecular discovery require Chip Design Physi
Slide 7: Bunsen Early Access Program Ongoing
Bunsen Early Access Program Ongoing What It Is Agentic AI Co-Scientist that helps understand, plan, execute, and interpret complex computational workflows Optimized to the Entire Platform Executes Schrödinger’s validated computational methods in small Analyze the protein-protein interface between my
Slide 8: Platform Has Broad Application Across Industrial Materials Design and Development
Platform Has Broad Application Across Industrial Materials Design and Development Consumer Catalysis & Energy Alloys, Organic Polymeric Semi- Complex Packaged Reactive Capture & Metals & Electronics Materials conductors Formulations Goods Systems Storage Ceramics Tailored solutions designed to reduc
Slide 9: Groundbreaking Battery Research Published in Nature
Groundbreaking Battery Research Published in Nature Publication Highlights • Up to 40% of lithium ions travel in clusters rather than alone • Lithium ion clusters govern the formation of the anode protective layer • Validated computational predictions with physical laboratory experiments Implication
Slide 10: 3Q26 Financial Highlights vs. 3Q25
3Q26 Financial Highlights vs. 3Q25 Three Months Ended September 30 3Q 2026 3Q 2025 % Change ($M) ($M) Software revenue $38.2 $35.9 6.2% Drug discovery revenue $24.2 $13.0 86% Contribution revenue $2.1 $5.4 (60%)* Total revenue $64.5 $54.3 19% Gross profit $38.3 $28.0 Software gross margin 75% 77% Op
Slide 11: Sequential Growth in Hosted Revenue
Sequential Growth in Hosted Revenue $17.2M $15.1M $12.0M 1Q26 2Q26 3Q26 Quarterly Hosted Revenue ($M) Y/Y Growth 11% 36% 49% % of Quarterly Software Revenue 34% 47% 45% Trailing 4 Quarters % of Software Revenue 27% 30% 32% 11
Slide 12: 2026 Financial Outlook and 2028 Financial Objectives
2026 Financial Outlook and 2028 Financial Objectives 2026 Financial and Operational Outlook 2028 Financial Objectives • ACV now expected to be in the range of $222 – • Durable ACV growth of 10-15% annually $232M, representing 12-17% growth over 2025 • Substantially complete transition to hosted • Dr
Slide 13: Therapeutics Strategy: Over $750M Cash Realized to Date
Therapeutics Strategy: Over $750M Cash Realized to Date Equity Stakes Drug Discovery Revenue Multiple M&A events → cash • Proprietary programs licensed to biopharma Current equity stakes in: • $56M revenue in 2025 • Nimbus Therapeutics • 22 collaborators since 2018 • Structure Therapeutics • Tectora
Slide 14: Extensive History of Monetization Events Spanning Co-invented Drugs & Co-Founded Companies
Extensive History of Monetization Events Spanning Co-invented Drugs & Schrödinger Co-Founded Companies Gilead Acquires Lilly Acquires Relay Therapeutics Takeda Acquires Nimbus ACC Inhibitor Petra Pharma Successful IPO Nimbus TYK2 Inhibitor $1.2B Undisclosed $400M Raised $6.0B April 2016* May 2020 Ju
Slide 15: Significant Upside Potential from Collaboration Programs
Significant Upside Potential from Collaboration Programs Partner Therapeutic Area Target Phase Remaining Milestones Royalties8 1 Inflammation (Psoriasis) TYK22 Filed Up to $100M7 - Cardiometabolic GLP-13 Phase 3 - - 1 IBD (UC/Crohn’s) α4β74 Phase 2 Undisclosed LSDs Cardiometabolic Amylin5 Phase1/2a
Slide 16: Significant Upside Potential from Collaboration Programs
Significant Upside Potential from Collaboration Programs Partner Therapeutic Area Target Phase Remaining Milestones Royalties2 1 Undisclosed Undisclosed Preclinical Undisclosed SD CNS Undisclosed Preclinical $482M MSDs to LDDs Undisclosed Undisclosed Preclinical $425M LSDs to LDDs Undisclosed Multip
Slide 17: Revolutionizing Medicines and Materials Discovery
Revolutionizing Medicines and Materials Discovery October 2026
Slide 18: Appendix
APPENDIX @ Schrédinger
Slide 19: Definitions
Definitions Annual Contract Value (ACV). Schrödinger tracks the ACV for each customer. With respect to contracts that have a duration of one year or less, or contracts of more than one year in duration that are billed annually, ACV is defined as the contract value billed during the applicable period
Slide 20: Definitions
Definitions Ongoing programs eligible for royalties. Schrödinger tracks the aggregate number of collaborative and partnered programs for which the company is eligible to receive any amount of future royalties on sales, if any. Numbers of collaborators since 2018. Schrödinger tracks the aggregate num
Slide 21: Non-GAAP Information
Non-GAAP Information Included in this presentation is certain financial information that has not been prepared in accordance with generally accepted accounting principles in the Three Months Ended September 30 United States (GAAP). The company presents adjusted EBITDA, which is a non-GAAP financial
Slide 22: Revolutionizing Medicines and Materials Discovery
Revolutionizing Medicines and Materials Discovery October 2026